News

EMA recommends approval of Revlimid® maintenance post-SCT for myeloma patients

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Revlimid (lenalidomide) as a maintenance treatment for newly diagnosed myeloma patients who have undergone high-dose therapy and stem cell transplantation (SCT). Revlimid is currently licensed for use in combination with dexamethasone for myeloma patients who have received…

Details

SMC turns down Kyprolis® and Darzalex®

The Scottish Medicines Consortium (SMC) has decided not to recommend the use of Kyprolis (carfilzomib) and Darzalex (daratumumab) as treatments for myeloma patients in Scotland. Kyprolis was considered in the relapsed and/or refractory setting for patients who have had at least one previous line of treatment in combination Revlimid® (lenalidomide) and dexamethasone but was turned…

Details

European patent granted for tasquinimod as a treatment for myeloma

The Swedish pharmaceutical company, Active Biotech, has announced that the European Patent Office has granted a patent covering the use of its drug, tasquinomod, as a potential treatment for myeloma. Tasquinimod is an immunomodulatory drug with anti-cancer and anti-angiogenic properties that is currently undergoing clinical testing in prostate cancer. Promising results have been achieved with…

Details

Phase II trial of BI-505 in myeloma terminated

The Swedish biotechnology company, BioInvent, has announced it has terminated a Phase I/ II trial of its lead drug BI-505 as a treatment in conjunction with high-dose therapy and stem cell transplantation (HDT-SCT) for newly diagnosed myeloma patients. This follows the verbal notice issued in November 2016 by the US Food and Drug Administration (FDA)…

Details

Key partnership formed to create the Myeloma Genome Project

Celgene, the Dana-Farber Cancer Institute and the University of Arkansas for Medical Sciences (UAMS) have announced that they have partnered to create the Myeloma Genome Project to compile high quality genetic and clinical data to improve diagnosis, prognosis and treatment for myeloma patients. The aim is to develop a strategy for classifying myeloma into subgroups…

Details

2016 ASH meeting highlights

Highlights of the key data presented at the 58th Annual Meeting of the American Society of Hematology (ASH) on 3 – 6 December 2016 in San Diego, California, USA include: Results from the Myeloma XI trial demonstrating how newly diagnosed patients benefitted from a response-adapted approach to treatment. Patients who switched to a different treatment…

Details

EU grants marketing approval for Ninlaro®

Takeda Pharmaceutical Company Ltd has announced that the European Commission has granted conditional marketing authorisation for Ninlaro (ixazomib) as a treatment in combination with Revlimid® and dexamethasone for relapsed and/or refractory myeloma patients who have received at least one previous line of treatment. This follows the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Details